| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Urticaria | 23 | 2019 | 472 | 5.15 | Why? |
| Mast Cells | 7 | 2019 | 370 | 2.69 | Why? |
| Rhinitis, Allergic | 12 | 2021 | 704 | 1.98 | Why? |
| Receptors, IgE | 4 | 2019 | 26 | 1.85 | Why? |
| Hypersensitivity | 11 | 2021 | 1137 | 1.61 | Why? |
| Stem Cell Factor | 2 | 2018 | 12 | 1.49 | Why? |
| Anti-Allergic Agents | 6 | 2018 | 167 | 1.37 | Why? |
| Cell Degranulation | 4 | 2019 | 130 | 1.23 | Why? |
| Histamine | 3 | 2019 | 61 | 1.09 | Why? |
| Skin | 7 | 2019 | 2096 | 0.79 | Why? |
| Cell Phone | 2 | 2017 | 750 | 0.77 | Why? |
| Receptors, Neuropeptide | 1 | 2018 | 30 | 0.77 | Why? |
| Gastritis | 1 | 2018 | 66 | 0.71 | Why? |
| Receptors, G-Protein-Coupled | 2 | 2018 | 309 | 0.71 | Why? |
| Interleukin-33 | 1 | 2019 | 120 | 0.69 | Why? |
| Efficiency | 3 | 2017 | 420 | 0.69 | Why? |
| Interleukin-4 | 1 | 2018 | 367 | 0.65 | Why? |
| Rhinitis | 4 | 2018 | 626 | 0.63 | Why? |
| Tretinoin | 1 | 2017 | 99 | 0.63 | Why? |
| Work Performance | 2 | 2017 | 186 | 0.62 | Why? |
| Nerve Tissue Proteins | 1 | 2018 | 319 | 0.61 | Why? |
| Asthma | 12 | 2021 | 4383 | 0.56 | Why? |
| Chronic Disease | 16 | 2018 | 5139 | 0.50 | Why? |
| Immunoglobulin E | 5 | 2020 | 557 | 0.49 | Why? |
| Allergens | 6 | 2021 | 728 | 0.49 | Why? |
| Histamine Release | 2 | 2017 | 9 | 0.49 | Why? |
| Dermatitis, Atopic | 2 | 2018 | 714 | 0.48 | Why? |
| Desensitization, Immunologic | 5 | 2021 | 574 | 0.46 | Why? |
| Omalizumab | 3 | 2018 | 158 | 0.45 | Why? |
| Quality of Life | 11 | 2018 | 9820 | 0.44 | Why? |
| TRPA1 Cation Channel | 2 | 2021 | 82 | 0.42 | Why? |
| NF-E2-Related Factor 2 | 3 | 2021 | 373 | 0.37 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.36 | Why? |
| Smartphone | 1 | 2019 | 1840 | 0.35 | Why? |
| Europe | 11 | 2019 | 12702 | 0.34 | Why? |
| Cell Cycle | 2 | 2019 | 329 | 0.32 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.32 | Why? |
| Piperazines | 2 | 2018 | 445 | 0.30 | Why? |
| Mobile Applications | 5 | 2019 | 3032 | 0.29 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.29 | Why? |
| Histamine H1 Antagonists | 3 | 2018 | 79 | 0.28 | Why? |
| Brassica | 2 | 2021 | 66 | 0.27 | Why? |
| Health Resources | 1 | 2017 | 2592 | 0.27 | Why? |
| Fermentation | 2 | 2020 | 156 | 0.26 | Why? |
| Diet | 4 | 2020 | 2052 | 0.26 | Why? |
| Psoriasis | 1 | 2017 | 1739 | 0.26 | Why? |
| Skin Diseases | 1 | 2019 | 2509 | 0.23 | Why? |
| Immunologic Tests | 1 | 2004 | 445 | 0.23 | Why? |
| Adrenal Cortex Hormones | 3 | 2021 | 6537 | 0.23 | Why? |
| Dermatitis, Allergic Contact | 2 | 2018 | 185 | 0.22 | Why? |
| Skin Tests | 2 | 2017 | 229 | 0.22 | Why? |
| Vegetables | 2 | 2020 | 340 | 0.22 | Why? |
| Cold Temperature | 2 | 2017 | 260 | 0.21 | Why? |
| Algorithms | 2 | 2017 | 7346 | 0.21 | Why? |
| Pollen | 2 | 2021 | 137 | 0.21 | Why? |
| TRPV Cation Channels | 1 | 2021 | 88 | 0.20 | Why? |
| Yin-Yang | 1 | 2019 | 1 | 0.20 | Why? |
| Histidine Decarboxylase | 1 | 2019 | 3 | 0.20 | Why? |
| Sublingual Immunotherapy | 1 | 2020 | 88 | 0.20 | Why? |
| Spices | 1 | 2020 | 130 | 0.20 | Why? |
| Sinusitis | 2 | 2017 | 649 | 0.20 | Why? |
| Phthalazines | 1 | 2018 | 26 | 0.19 | Why? |
| Syk Kinase | 1 | 2018 | 32 | 0.19 | Why? |
| Humans | 68 | 2021 | 930598 | 0.19 | Why? |
| Patients | 1 | 2007 | 1167 | 0.19 | Why? |
| Antibodies, Anti-Idiotypic | 1 | 2018 | 93 | 0.18 | Why? |
| Antigens, Differentiation, B-Lymphocyte | 1 | 2018 | 54 | 0.18 | Why? |
| Interleukin-5 | 1 | 2018 | 138 | 0.18 | Why? |
| RNA Interference | 2 | 2019 | 534 | 0.18 | Why? |
| Pilot Projects | 4 | 2018 | 5182 | 0.18 | Why? |
| Basophils | 1 | 2018 | 179 | 0.18 | Why? |
| Keratoderma, Palmoplantar | 1 | 2017 | 24 | 0.18 | Why? |
| Mastocytosis, Systemic | 1 | 2017 | 44 | 0.18 | Why? |
| Peritoneal Neoplasms | 1 | 2018 | 110 | 0.18 | Why? |
| Skin Aging | 1 | 2018 | 55 | 0.17 | Why? |
| Tryptases | 1 | 2017 | 37 | 0.17 | Why? |
| Quantitative Trait, Heritable | 1 | 2017 | 26 | 0.17 | Why? |
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2018 | 121 | 0.17 | Why? |
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 230 | 0.17 | Why? |
| Rhinitis, Allergic, Seasonal | 3 | 2017 | 121 | 0.17 | Why? |
| Cells, Cultured | 2 | 2019 | 5835 | 0.17 | Why? |
| Cytoplasmic Granules | 1 | 2017 | 53 | 0.17 | Why? |
| Antigens, Surface | 1 | 2018 | 181 | 0.16 | Why? |
| Bacterial Infections | 1 | 2010 | 2229 | 0.16 | Why? |
| Gene Knockdown Techniques | 1 | 2017 | 347 | 0.16 | Why? |
| Research | 3 | 2018 | 2115 | 0.15 | Why? |
| Foot | 1 | 2017 | 195 | 0.15 | Why? |
| Internet | 3 | 2020 | 6204 | 0.15 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.15 | Why? |
| Administration, Topical | 1 | 2017 | 272 | 0.15 | Why? |
| Environment, Controlled | 1 | 2017 | 129 | 0.15 | Why? |
| Eosinophils | 2 | 2020 | 848 | 0.15 | Why? |
| Lectins | 1 | 2018 | 311 | 0.15 | Why? |
| Benzimidazoles | 1 | 2018 | 275 | 0.15 | Why? |
| Ultraviolet Rays | 1 | 2005 | 1272 | 0.15 | Why? |
| Helicobacter Infections | 1 | 2018 | 216 | 0.14 | Why? |
| Common Cold | 1 | 2021 | 645 | 0.14 | Why? |
| Helicobacter pylori | 1 | 2018 | 262 | 0.14 | Why? |
| Interleukin-1 | 1 | 2018 | 438 | 0.14 | Why? |
| Cell Survival | 2 | 2017 | 1581 | 0.14 | Why? |
| Wound Healing | 1 | 2018 | 424 | 0.13 | Why? |
| Ligands | 1 | 2018 | 1300 | 0.13 | Why? |
| Signal Transduction | 3 | 2020 | 7207 | 0.12 | Why? |
| Hand | 1 | 2017 | 449 | 0.12 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.12 | Why? |
| Virus Diseases | 1 | 2010 | 3779 | 0.12 | Why? |
| Multimorbidity | 1 | 2018 | 703 | 0.12 | Why? |
| Food Hypersensitivity | 1 | 1998 | 397 | 0.12 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Conjunctivitis | 1 | 2017 | 318 | 0.12 | Why? |
| Office Visits | 1 | 2017 | 489 | 0.12 | Why? |
| Dermatology | 2 | 2011 | 1999 | 0.12 | Why? |
| Inhalation Exposure | 1 | 2017 | 405 | 0.12 | Why? |
| RNA, Small Interfering | 1 | 2017 | 817 | 0.12 | Why? |
| Anti-Asthmatic Agents | 1 | 2017 | 427 | 0.12 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.12 | Why? |
| Surveys and Questionnaires | 7 | 2018 | 43792 | 0.12 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 9335 | 0.12 | Why? |
| Piperidines | 1 | 2018 | 795 | 0.12 | Why? |
| Anaphylaxis | 1 | 2021 | 940 | 0.11 | Why? |
| Databases, Factual | 1 | 2007 | 6248 | 0.11 | Why? |
| Information Dissemination | 1 | 2007 | 2986 | 0.11 | Why? |
| Loratadine | 1 | 2010 | 18 | 0.11 | Why? |
| Histamine H1 Antagonists, Non-Sedating | 1 | 2010 | 33 | 0.11 | Why? |
| Ninhydrin | 1 | 2010 | 2 | 0.11 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.11 | Why? |
| Gene Expression | 2 | 2018 | 3332 | 0.11 | Why? |
| Rhinitis, Allergic, Perennial | 1 | 2010 | 36 | 0.11 | Why? |
| Precision Medicine | 2 | 2017 | 1477 | 0.10 | Why? |
| Respiratory Tract Infections | 1 | 2010 | 6817 | 0.10 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.10 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.10 | Why? |
| Allergists | 2 | 2021 | 266 | 0.10 | Why? |
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 896 | 0.09 | Why? |
| Telemedicine | 1 | 2019 | 25032 | 0.09 | Why? |
| Immunosuppressive Agents | 1 | 2006 | 6331 | 0.08 | Why? |
| Antioxidants | 3 | 2021 | 1593 | 0.08 | Why? |
| Adaptive Immunity | 1 | 2018 | 2585 | 0.08 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.08 | Why? |
| Sleep Wake Disorders | 1 | 2017 | 1463 | 0.08 | Why? |
| Ficusin | 1 | 2005 | 5 | 0.08 | Why? |
| Female | 22 | 2020 | 380317 | 0.08 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Dermatitis, Occupational | 1 | 2010 | 310 | 0.07 | Why? |
| Male | 19 | 2021 | 367725 | 0.07 | Why? |
| Adult | 17 | 2020 | 244371 | 0.07 | Why? |
| Environmental Monitoring | 1 | 2017 | 3143 | 0.07 | Why? |
| Immunization | 3 | 2018 | 2019 | 0.07 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.06 | Why? |
| Biological Products | 1 | 2018 | 2331 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2018 | 4418 | 0.06 | Why? |
| Public Health Surveillance | 1 | 2017 | 3129 | 0.06 | Why? |
| Psychometrics | 1 | 2011 | 1269 | 0.06 | Why? |
| Biosensing Techniques | 1 | 2017 | 2116 | 0.06 | Why? |
| Health Services Needs and Demand | 1 | 2018 | 3419 | 0.06 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.06 | Why? |
| Population Surveillance | 2 | 2017 | 4967 | 0.06 | Why? |
| Advisory Committees | 1 | 2010 | 1418 | 0.06 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.06 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Photosensitizing Agents | 1 | 2005 | 279 | 0.06 | Why? |
| Amyloidosis | 1 | 2004 | 178 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Lactobacillales | 1 | 2020 | 20 | 0.06 | Why? |
| In Vitro Techniques | 1 | 2005 | 1027 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.05 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
| Prevalence | 4 | 2018 | 25773 | 0.05 | Why? |
| Young Adult | 7 | 2020 | 93724 | 0.05 | Why? |
| Sebum | 1 | 2018 | 9 | 0.05 | Why? |
| Ecology | 1 | 2020 | 140 | 0.05 | Why? |
| Laser-Doppler Flowmetry | 1 | 2018 | 32 | 0.05 | Why? |
| Eccrine Glands | 1 | 2018 | 30 | 0.05 | Why? |
| Air Pollutants | 1 | 2017 | 3110 | 0.05 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.05 | Why? |
| Epinephrine | 1 | 2021 | 323 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.05 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.05 | Why? |
| Radio Waves | 1 | 2018 | 27 | 0.05 | Why? |
| Spectrum Analysis | 1 | 2018 | 112 | 0.05 | Why? |
| Immune Complex Diseases | 1 | 2018 | 22 | 0.05 | Why? |
| Cross-Sectional Studies | 4 | 2020 | 53120 | 0.05 | Why? |
| Disease Resistance | 1 | 2020 | 236 | 0.05 | Why? |
| Receptors, Interferon | 1 | 2018 | 64 | 0.04 | Why? |
| Hyaluronan Receptors | 1 | 2018 | 61 | 0.04 | Why? |
| Information Technology | 1 | 2021 | 278 | 0.04 | Why? |
| Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 46 | 0.04 | Why? |
| Betula | 1 | 2017 | 10 | 0.04 | Why? |
| Permeability | 1 | 2018 | 238 | 0.04 | Why? |
| Poaceae | 1 | 2017 | 23 | 0.04 | Why? |
| Family Practice | 1 | 2004 | 472 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2018 | 10649 | 0.04 | Why? |
| Child | 7 | 2018 | 70012 | 0.04 | Why? |
| Acute Disease | 1 | 2010 | 6029 | 0.04 | Why? |
| Treatment Outcome | 6 | 2018 | 51732 | 0.04 | Why? |
| Coculture Techniques | 1 | 2018 | 258 | 0.04 | Why? |
| Germany | 2 | 2017 | 9196 | 0.04 | Why? |
| Keratinocytes | 1 | 2018 | 119 | 0.04 | Why? |
| Patient Education as Topic | 1 | 2007 | 1476 | 0.04 | Why? |
| Angioedema | 1 | 2018 | 111 | 0.04 | Why? |
| Microscopy, Confocal | 1 | 2018 | 343 | 0.04 | Why? |
| Histamine Antagonists | 1 | 2018 | 203 | 0.04 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.04 | Why? |
| Dose-Response Relationship, Drug | 1 | 2006 | 3776 | 0.04 | Why? |
| Spectrum Analysis, Raman | 1 | 2018 | 311 | 0.04 | Why? |
| Administration, Intranasal | 1 | 2020 | 1132 | 0.04 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2018 | 632 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Cosmetic Techniques | 1 | 2018 | 167 | 0.04 | Why? |
| Administration, Inhalation | 1 | 2021 | 1647 | 0.04 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.04 | Why? |
| Aged | 7 | 2021 | 215776 | 0.04 | Why? |
| Biological Assay | 1 | 2018 | 367 | 0.04 | Why? |
| Patient Reported Outcome Measures | 1 | 2020 | 912 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Hydrogen-Ion Concentration | 1 | 2018 | 993 | 0.03 | Why? |
| Eosinophilia | 1 | 2018 | 292 | 0.03 | Why? |
| Pain | 2 | 2018 | 1084 | 0.03 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2020 | 1136 | 0.03 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.03 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.03 | Why? |
| Microcirculation | 1 | 2018 | 447 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| Erythema | 1 | 2018 | 400 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.03 | Why? |
| Adolescent | 6 | 2020 | 86841 | 0.03 | Why? |
| Clinical Decision-Making | 2 | 2017 | 3755 | 0.03 | Why? |
| Animals | 3 | 2017 | 78931 | 0.03 | Why? |
| Depression | 1 | 2017 | 14116 | 0.03 | Why? |
| Life Style | 1 | 2006 | 2708 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2019 | 15909 | 0.03 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.03 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.03 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2010 | 17020 | 0.03 | Why? |
| Research Design | 2 | 2018 | 5830 | 0.03 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Evidence-Based Practice | 1 | 2017 | 693 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Tomography, Optical Coherence | 1 | 2018 | 1008 | 0.03 | Why? |
| United States | 1 | 2018 | 46150 | 0.03 | Why? |
| Risk Factors | 1 | 2019 | 71621 | 0.03 | Why? |
| Oxidative Stress | 1 | 2021 | 2050 | 0.02 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| Patch Tests | 1 | 2010 | 114 | 0.02 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.02 | Why? |
| Dendritic Cells | 1 | 2018 | 1330 | 0.02 | Why? |
| Prospective Studies | 3 | 2018 | 43301 | 0.02 | Why? |
| Geriatric Assessment | 1 | 2017 | 1372 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Double-Blind Method | 1 | 1998 | 5988 | 0.02 | Why? |
| Police | 1 | 2010 | 243 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2020 | 1961 | 0.02 | Why? |
| Stress, Psychological | 1 | 2010 | 10231 | 0.02 | Why? |
| Pain Measurement | 1 | 2010 | 533 | 0.02 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.02 | Why? |
| Hospitalization | 1 | 2017 | 54280 | 0.02 | Why? |
| Consensus | 1 | 2021 | 6345 | 0.02 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| CD18 Antigens | 1 | 2004 | 19 | 0.02 | Why? |
| Disease Progression | 2 | 2017 | 13580 | 0.02 | Why? |
| Lymphocytes | 1 | 2018 | 3056 | 0.02 | Why? |
| Cities | 1 | 2017 | 4937 | 0.02 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Pedigree | 1 | 2004 | 502 | 0.02 | Why? |
| Longitudinal Studies | 1 | 1998 | 9893 | 0.02 | Why? |
| Poland | 1 | 2011 | 2368 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Arthralgia | 1 | 2004 | 173 | 0.02 | Why? |
| Comorbidity | 2 | 2017 | 34796 | 0.01 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Leukocytosis | 1 | 2004 | 280 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Risk Assessment | 1 | 2006 | 25439 | 0.01 | Why? |
| Triage | 1 | 2021 | 7151 | 0.01 | Why? |
| Time Factors | 1 | 2004 | 31397 | 0.01 | Why? |
| Syndrome | 1 | 2004 | 1310 | 0.01 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Infant | 1 | 2018 | 30274 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.01 | Why? |